CXCR2 and asthma: AZD5069 is a selective CXCR2 antagonist developed by AstraZeneca to prevent neutrophil recruitment without hampering neutrophil immune defences.[57] AZD5069 significantly reduced neutrophil infiltration in sputum and bronchial biopsies in patients with severe asthma (90% inhibition).[58] However, concerns about the ability of AZD5069 to treat poorly controlled severe NA also exist.